A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521
Primary Purpose
Solid Tumor
Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
BYON3521
Sponsored by

About this trial
This is an interventional treatment trial for Solid Tumor focused on measuring ADC, c-MET, solid tumors
Eligibility Criteria
Inclusion Criteria:
- Patient with histologically-confirmed, locally advanced or metastatic cancer who has progressed on standard therapy or for whom no standard therapy exists:
- Part 1 (dose-escalation): solid tumours of any origin;
Part 2 (expansion):
- Cohort A: renal cell carcinoma (PRCC + CCRCC);
- Cohort B: uveal melanoma (UM);
- Cohort C: head and neck squamous cell carcinoma (HNSCC);
- Cohort D: other cancers (non-RCC, non-UM and non-HNSCC); Part 1: Tumour c-MET positive membrane staining by immunohistochemistry (IHC)a and/or MET amplification by dual In Situ Hybridization (dISH)a and/or known MET-mutation; Part 2: Tumour c-MET positive membrane staining by immunohistochemistry (IHC) and MET-amplification by dual In Situ Hybridization (dISH), or tumour c-MET positive membrane staining by immunohistochemistry (IHC) and MET-mutation (excluding exon14m);
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1;
- Adequate organ function
Exclusion Criteria:
- Having been treated with:
- Trastuzumab duocarmazine (SYD985) at any time
- Other anticancer therapy within 4 weeks or as defined in the protocol
- History or presence of keratitis, glomerulonephritis, idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterans), drug-induced or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan;
- History (within 6 months prior to start IMP) or presence of clinically significant cardiovascular disease such as unstable angina, congestive heart failure, myocardial infarction, uncontrolled hypertension, or cardiac arrhythmia requiring medication;
- Symptomatic brain metastases, brain metastases requiring steroids or treatment for brain metastases within 8 weeks
Sites / Locations
- Institut Jules BordetRecruiting
- Istituto Europeo di OncologiaRecruiting
- RadboudRecruiting
- Royal MarsdenRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
BYON3521
Arm Description
c-MET targeting Antibody-Drug Conjugate
Outcomes
Primary Outcome Measures
Incidence of dose-limiting toxicities
Part 1
Secondary Outcome Measures
Objective response rate
Part 2
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05323045
Brief Title
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521
Official Title
A First-in-human Dose-escalation and Expansion Trial With the Antibody-drug Conjugate BYON3521 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With c-MET Expressing Locally Advanced or Metastatic Solid Tumours
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 21, 2022 (Actual)
Primary Completion Date
January 1, 2025 (Anticipated)
Study Completion Date
March 1, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Byondis B.V.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is the first-in-human trial with BYON3521, an antibody-drug conjugate (ADC) comprising a humanized IgG1 monoclonal antibody directed against the c-MET receptor covalently conjugated to a duocarmycin-containing linker-drug.
Detailed Description
This trial includes a dose-escalation part (Part 1) in which the MTD and RDE will be determined, and an expansion part (Part 2) to evaluate efficacy and safety in specific patient cohorts.
BYON3521 is an ADC comprising a humanized IgG1 monoclonal antibody (mAb) directed against the c-MET receptor covalently and site-specifically conjugated to a duocarmycin-containing linkerdrug.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumor
Keywords
ADC, c-MET, solid tumors
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
BYON3521
Arm Type
Experimental
Arm Description
c-MET targeting Antibody-Drug Conjugate
Intervention Type
Drug
Intervention Name(s)
BYON3521
Intervention Description
BYON3521 (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
Primary Outcome Measure Information:
Title
Incidence of dose-limiting toxicities
Description
Part 1
Time Frame
21 days
Secondary Outcome Measure Information:
Title
Objective response rate
Description
Part 2
Time Frame
21 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient with histologically-confirmed, locally advanced or metastatic cancer who has progressed on standard therapy or for whom no standard therapy exists:
Part 1 (dose-escalation): solid tumours of any origin;
Part 2 (expansion):
Cohort A: Non-squamous non small cell lung cancer (non-squamous NSCLC);
Cohort B: Gynaecological cancers: ovarian cancer, endometrial cancer, cervical cancer;
Cohort C: Pancreatic adenocarcinoma (PA);
Cohort D: Uveal melanoma (UM).
c-MET prevalence confirmed by:
Part 1: Tumour c-MET positive membrane staining by immunohistochemistry (IHC) and/or MET amplification by dual In Situ Hybridization (dISH) and/or known MET-mutation;
Part 2: Tumour c-MET membrane expression by immunohistochemistry (IHC score ≥ 2+) as determined by the central laboratory on most recent available/obtained tumour material from a site not previously irradiated;
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1;
Adequate organ function
Exclusion Criteria:
Having been treated with:
Trastuzumab duocarmazine (SYD985) at any time;
Other anticancer therapy within 4 weeks or as defined in the protocol;
History or presence of keratitis, glomerulonephritis, idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterans), drug-induced or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan;
History (within 6 months prior to start IMP) or presence of clinically significant cardiovascular disease such as unstable angina, congestive heart failure, myocardial infarction, uncontrolled hypertension, or cardiac arrhythmia requiring medication;
Symptomatic brain metastases, brain metastases requiring steroids or treatment for brain metastases within 8 weeks
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tanya Vermaas
Phone
+31 (0)24 679 5100
Email
clinicaltrials@byondis.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tanya Vermaas
Organizational Affiliation
Byondis B.V., The Netherlands
Official's Role
Study Director
Facility Information:
Facility Name
Institut Jules Bordet
City
Brussels
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nuria Kotecki
Facility Name
Istituto Europeo di Oncologia
City
Milan
ZIP/Postal Code
1070
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Curigliano Giuseppe
Facility Name
Radboud
City
Nijmegen
ZIP/Postal Code
6500HB
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carla van Herpen
Facility Name
Royal Marsden
City
London
ZIP/Postal Code
SM2 5PT
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Udai Banerji
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521
We'll reach out to this number within 24 hrs